Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT): a Single Centre, Phase II, Dose De-escalation, Non-inferiority, Clinical Trial.

NCT05258422 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.

NCT NCT05258422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05258422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT): a Single Centre, Phase II, Dose De-escalation, Non-inferiority, Clinical Trial.
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
July 1, 2023
Completion date
December 31, 2031
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arrhythmia, arrhythmic storm, radiation toxicity, ventricular tachycardia